Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 17/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091959 | 0.91 | LMNA (0.53) | FFAR2MEN1KMT2ALMNA | |
| SCHEMBL6094823 | 0.91 | LMNA (0.53) | FFAR2MEN1KMT2ALMNA | |
| SCHEMBL20707804 | 0.84 | ADORA2A (0.46) | KMT2A | |
| SCHEMBL4367597 | 0.82 | FFAR2 (0.49) | FFAR2MEN1KMT2ALMNA | |
| SCHEMBL4365197 | 0.82 | FFAR2 (0.49) | FFAR2MEN1KMT2ALMNA | |
| SCHEMBL4367943 | 0.82 | FFAR2 (0.49) | FFAR2MEN1KMT2ALMNA | |
| SCHEMBL4372770 | 0.79 | KDR (0.55) | FFAR2MEN1KMT2ALMNA | |
| SCHEMBL4367691 | 0.77 | ALDH1A1 (0.48) | MEN1KMT2ALMNA | |
| SCHEMBL6092098 | 0.77 | HSD17B10 (0.46) | — | |
| SCHEMBL4368860 | 0.73 | ROCK2 (0.51) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622592-B2 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | AR, SHBG, BRCA1 | FFAR2 219/4885MEN1 3556/4885KMT2A 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.